ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Hold” by Analysts

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has been given a consensus rating of “Hold” by the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $30.6667.

SPRY has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Roth Mkm initiated coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SPRY. American Assets Inc. bought a new stake in shares of ARS Pharmaceuticals during the third quarter valued at approximately $553,000. Geode Capital Management LLC boosted its stake in ARS Pharmaceuticals by 6.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,342,387 shares of the company’s stock valued at $23,427,000 after purchasing an additional 81,910 shares during the last quarter. Ardsley Advisory Partners LP boosted its stake in ARS Pharmaceuticals by 46.2% during the 2nd quarter. Ardsley Advisory Partners LP now owns 475,000 shares of the company’s stock valued at $8,289,000 after purchasing an additional 150,000 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth $1,832,000. Finally, Levin Capital Strategies L.P. raised its stake in shares of ARS Pharmaceuticals by 157.6% in the third quarter. Levin Capital Strategies L.P. now owns 764,294 shares of the company’s stock worth $7,681,000 after purchasing an additional 467,647 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Stock Down 0.6%

Shares of ARS Pharmaceuticals stock opened at $9.28 on Friday. ARS Pharmaceuticals has a 1 year low of $6.66 and a 1 year high of $18.90. The firm has a market cap of $917.33 million, a price-to-earnings ratio of -11.46 and a beta of 0.79. The company has a 50-day moving average of $10.42 and a 200 day moving average of $10.37. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.